` 603882 (Guangzhou Kingmed Diagnostics Group Co Ltd) vs Shanghai Composite Comparison - Alpha Spread

603882
vs
S
Shanghai Composite

Over the past 12 months, Guangzhou Kingmed Diagnostics Group Co Ltd has underperformed Shanghai Composite, delivering a return of -16% compared to the Shanghai Composite's +15% growth.

Stocks Performance
603882 vs Shanghai Composite

Loading
603882
Shanghai Composite
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
603882 vs Shanghai Composite

Loading
603882
Shanghai Composite
Difference
www.alphaspread.com

Performance By Year
603882 vs Shanghai Composite

Loading
603882
Shanghai Composite
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Guangzhou Kingmed Diagnostics Group Co Ltd vs Peers

Shanghai Composite
603882
CVS
CGN
CI
FRE
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Guangzhou Kingmed Diagnostics Group Co Ltd
Glance View

Market Cap
13.3B CNY
Industry
Health Care

Guangzhou Kingmed Diagnostics Group Co Ltd has crafted its journey in the healthcare industry with precision and analytical prowess. Emerging in the early 2000s, Kingmed Diagnostics tapped into a burgeoning market niche—offering diagnostic testing services to hospitals, clinics, and other medical institutions. With a blend of advanced technology and extensive scientific expertise, the company provides a range of services, from routine clinical testing to esoteric evaluations that require more sophisticated techniques. Kingmed’s laboratories, strategically established across China, facilitate a seamless operation that processes millions of tests annually, ensuring timely and accurate results. This operational efficiency not only supports healthcare providers in delivering informed patient care but also positions Kingmed at the forefront of diagnostic innovation. Revenue streams flow through service contracts with healthcare facilities and direct partnerships where they provide specialized testing offerings that institutions may not have the infrastructure to perform in-house. By leveraging economies of scale, Kingmed achieves cost efficiencies, which in turn afford competitive pricing structures, further securing its market position. Complementing its robust diagnostic services, the company also invests in research and development initiatives, continuously enhancing its test portfolio. This commitment to innovation ensures that they stay relevant in the ever-evolving healthcare landscape, capturing new opportunities and expanding their market reach. Through this strategic framework, Guangzhou Kingmed Diagnostics not only sustains its financial growth but also fortifies its leadership in the diagnostic services sector.

Intrinsic Value
29.46 CNY
Undervaluation 3%
Intrinsic Value
Price
Back to Top